


Emlenoflast

Cat. No.:	HY-137245
CAS No.:	1995067-59-8
Molecular Formula:	C ₁₉ H ₂₄ N ₄ O ₃ S
Molecular Weight:	388.48
Target:	NOD-like Receptor (NLR)
Pathway:	Immunology/Inflammation
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (321.77 mM; Need ultrasonic)

Concentration	Solvent	Mass	1 mg	5 mg	10 mg
			1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.5741 mL	12.8707 mL	25.7414 mL
	5 mM		0.5148 mL	2.5741 mL	5.1483 mL
	10 mM		0.2574 mL	1.2871 mL	2.5741 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Emlenoflast (MCC7840), a sulfonylurea, is a potent and selective inhibitor of NLRP3 inflammasome, with an IC₅₀ of <100 nM. Emlenoflast can be used for the research of inflammatory diseases^{[1][2]}.

IC₅₀ & Target

NLRP3 inflammasome
<100 nM (IC₅₀)

In Vitro

Emlenoflast, a MCC950 analogue, shows useful activity in the inhibition of activation of the NLRP3 inflammasome, with an IC₅₀ of <100 nM^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Emlenoflast (4 mg/kg; i.v.) exhibits the half-life (3.39 h), AUC_{0-last} (107097 ng•h/mL) and CL (0.621 mL/min/kg) in mice^[2].
Emlenoflast (20 mg/kg; p.o.) exhibits the oral bioavailability (67.2%), C_{max} (60467 ng/mL) and half-life (5.02 h) in mice^[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6 mice (7-9 weeks) ^[2]
---------------	--

Dosage:	4 mg/kg for i.v. and 20 mg/kg for p.o. (Pharmacokinetic Analysis)
Administration:	A single intravenous bolus or oral gavage
Result:	I.v.: $t_{1/2}$ =3.39 h; AUC_{0-last} =107097 ng·h/mL; CL=0.621 mL/min/kg. P.o.: F=67.2%; C_{max} =60467 ng/mL; $t_{1/2}$ =5.02 h.

REFERENCES

[1]. El-Sharkawy LY, et, al. Inhibiting the NLRP3 Inflammasome. *Molecules*. 2020 Nov 25;25(23):5533.

[2]. O'Neill L, et, al. Sulfonylureas and related compounds and use of same. WO2016131098A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA